LUBIPROSTONE
| Brand name | AMITIZA |
|---|---|
| Active ingredient | LUBIPROSTONE |
| Strength | 8MCG |
| Dosage form | CAPSULE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | April 2008 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 8026393 | October 2027 | product |
| 8779187 | January 2027 | product |
| 8338639 | January 2027 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.